Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Preferred Stock Liabilities (2019 - 2021)

Lyell Immunopharma's Preferred Stock Liabilities history spans 3 years, with the latest figure at $1.0 billion for Q1 2021.

  • For Q1 2021, Preferred Stock Liabilities changed N/A year-over-year to $1.0 billion; the TTM value through Mar 2021 reached $1.0 billion, changed N/A, while the annual FY2020 figure was $1.0 billion, 94.73% up from the prior year.
  • Preferred Stock Liabilities for Q1 2021 was $1.0 billion at Lyell Immunopharma, roughly flat from $1.0 billion in the prior quarter.
  • Across five years, Preferred Stock Liabilities topped out at $1.0 billion in Q2 2020 and bottomed at $519.2 million in Q4 2019.
  • The 3-year median for Preferred Stock Liabilities is $1.0 billion (2020), against an average of $912.6 million.
  • The largest YoY upside for Preferred Stock Liabilities was 94.73% in 2020 against a maximum downside of 94.73% in 2020.
  • A 3-year view of Preferred Stock Liabilities shows it stood at $519.2 million in 2019, then surged by 94.73% to $1.0 billion in 2020, then changed by 0.0% to $1.0 billion in 2021.
  • Per Business Quant, the three most recent readings for LYEL's Preferred Stock Liabilities are $1.0 billion (Q1 2021), $1.0 billion (Q4 2020), and $1.0 billion (Q3 2020).